In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Senior Writer

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest From Francesca Bruce

Premature Filings Add To EU Regulatory Resource Challenge

The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.

Europe EU Legislative Reform

Early Advice Could Help Companies Maintain EU Conditional Marketing Authorizations

The number of conditional marketing authorization non-renewals could increase.

Europe Market Access

El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices

El Salvador has approved a new law that will establish a new regulatory body responsible for authorizing medicines and setting prices.

El Salvador Policy

UK Voluntary Pricing Deal: Commercial Framework To Better Align With New Regulatory Pathways

NHS England has committed to two pilots on innovative pricing models for advanced therapies under the UK’s new voluntary pricing agreement for new medicines.

Europe United Kingdom

El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices

El Salvador has approved a law that will establish a new regulatory body responsible for authorizing medicines and setting prices.

El Salvador Policy

Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy

CSL’s Hemgenix is the latest expensive gene therapy to come under scrutiny from the BeNeLuxA cross-country coalition.

Europe Belgium
See All
UsernamePublicRestriction

Register